Dilafruz Juraeva

Frankfurter Str. 250
Darmstadt, HE 64293, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project.

Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project.

Journal: The journal of liquid biopsy
Published: June 15, 2026

Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.

Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 13, 2024

ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.

ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 19, 2024

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.

Journal: The Lancet. Oncology
Published: January 19, 2024

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.

Journal: Cell reports. Medicine
Published: October 05, 2022

CONET: copy number event tree model of evolutionary tumor history for single-cell data.

CONET: copy number event tree model of evolutionary tumor history for single-cell data.

Journal: Genome biology
Published: August 30, 2021

The genomic and transcriptional landscape of primary central nervous system lymphoma.

The genomic and transcriptional landscape of primary central nervous system lymphoma.

Journal: Nature communications
Published: August 19, 2021

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.

Journal: JCO precision oncology
Published: March 30, 2021

Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines.

Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines.

Journal: Scientific reports
Published: January 22, 2021

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.

Journal: The New England journal of medicine
Published: May 30, 2020

Feature selection strategies for drug sensitivity prediction.

Feature selection strategies for drug sensitivity prediction.

Journal: Scientific reports
Published: December 13, 2019

Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential.

Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 14, 2018
Showing 1-12 of 24

Last Updated: 09/26/2026